The randomized trial announced by Eli Lilly with NIAID will investigate the efficacy and safety of as a potential treatment for patients with serious COVID-19 infections. The study will begin in the US in late April with planned expansion to additional sites in Europe and Asia, with the results being expected within the next two months. This new trial joins a Canadian government randomised trial already underway assessing baricitinib as a potential treatment. TechCrunch
Tuesday, April 14, 2020
Potential new treatment for COVID-19 uncovered by BenevolentAI enters trials
The randomized trial announced by Eli Lilly with NIAID will investigate the efficacy and safety of as a potential treatment for patients with serious COVID-19 infections. The study will begin in the US in late April with planned expansion to additional sites in Europe and Asia, with the results being expected within the next two months. This new trial joins a Canadian government randomised trial already underway assessing baricitinib as a potential treatment. TechCrunch
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment